Equity Overview
Price & Market Data
Price: $2.66
Daily Change: -$0.05 / 1.88%
Daily Range: $2.60 - $2.81
Market Cap: $265,767,248
Daily Volume: 79,742
Performance Metrics
1 Week: 5.98%
1 Month: 63.69%
3 Months: 74.43%
6 Months: 66.25%
1 Year: 30.39%
YTD: 47.78%
Company Details
Employees: 222
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.